Breaking News

SCM Pharma Facility Approved by the FDA

December 3, 2013

Prepares for commercial launch of BTG’s Varithena

SCM Pharma’s clinical development and manufacturing facility in Prudhoe, UK, has been approved by the FDA. The inspection was triggered by the preparation for the commercial launch of BTG’s Varithena (polidocanol injectable foam), following clinical development consultation for the product. 
The FDA has approved BTG’s varicose veins treatment (previously known as Varisolve PEM), which uses an injectable, pharmaceutical-grade foam to dissolve the veins as an alternative to surgery. SCM’s Prudhoe site was named on the NDA as a one of the commercial suppliers for the product. SCM Pharma has worked with BTG since 2005 on process development, sterile manufacturing, packaging and distribution to support clinical trial studies in the U.S.
Dianne Sharp, managing director at SCM Pharma, said, “The FDA approval at our headquarters in Prudhoe tops off a milestone year for our business after gaining our MHRA license for our new commercial manufacturing facility in Newburn in the summer. This approval represents another major project where we have played a major developmental and production role to take a client with a complex product from early phase trials to commercial. We will be looking to immediately strengthen our U.S. team and presence as this approval will no doubt trigger more demand for our small-scale clinical and contract manufacturing services in North America.”

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016